The Effect of GCSF in the Treatment of ALS Patients

• Status: Completed
• Trial end date: 2013-11-01
• Target enrollment: 0
• Participant gender: All

Summary

The aim of this study is to evaluate the effect off Granulocyte Colony Stimulating Factor (GCSF) in the treatment of Amyotrophic Lateral Sclerosis (ALS) patients.

• Phase: Phase 2/Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Tehran University of Medical Sciences
• Treatments: Lenograstim; Sargramostim

Criteria

Inclusion Criteria:

• age between 18 and 85

• definite or probable ALS according to revised El Escorial criteria

• maximum 2 years from initiation of symptoms to study entry

• mild to moderate disability according to revised ALS functional rating scale (ALSFRS-r)

Exclusion Criteria:

• familial ALS

• pregnancy or lactation

• myeloproliferative or hematologic disorders

• active immunological disease

• liver or renal or heart disease

• HIV positive

• significant cognitive disorder

• hypersensitivity to GCSF